ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2026)
ARS Pharmaceuticals (SPRY) posted Retained Earnings of -$355.2 million for Q1 2026, down 284276.8% sequentially from $125000.0 in Q4 2025, and down 191.99% YoY from $386.1 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Retained Earnings for 6 years, with the latest figure at -$355.2 million in Q1 2026.
- Quarterly Retained Earnings fell 191.99% year-over-year to -$355.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$355.2 million (down 191.99% YoY) and the FY2025 annual result came in at $125000.0, down 99.97% from the prior year.
- Retained Earnings slipped to -$355.2 million in Q1 2026 per SPRY's latest filing, from $125000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $510.6 million in Q2 2022 and troughed at -$355.2 million in Q1 2026.
- A 5-year average of $150.0 million and a median of $407000.0 in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings surged 537513.24% in 2024, then plunged 191.99% in 2026.
- Over 5 years, Retained Earnings stood at $407000.0 in 2022, then soared by 88844.47% to $362.0 million in 2023, then advanced by 4.94% to $379.9 million in 2024, then tumbled by 99.97% to $125000.0 in 2025, then sank by 284276.8% to -$355.2 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$355.2 million, $125000.0, and -$7000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 430.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 430.20 Mn |
| Mar 31, 2026 | -355.22 Mn |
| Dec 31, 2025 | 125,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -202.13 Mn |
| Mar 31, 2025 | 386.14 Mn |
| Dec 31, 2024 | 379.87 Mn |
| Sep 30, 2024 | 373.87 Mn |
| Jun 30, 2024 | 369.49 Mn |
| Mar 31, 2024 | 365.58 Mn |
| Dec 31, 2023 | 362.00 Mn |
| Sep 30, 2023 | 361.57 Mn |
| Jun 30, 2023 | -180,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Sep 30, 2022 | -1.62 Mn |
| Jun 30, 2022 | 510.61 Mn |
| Mar 31, 2022 | -1.25 Mn |
| Dec 31, 2021 | 10.98 Mn |
| Sep 30, 2021 | -162.80 Mn |